[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-d-25-hydroxylase-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-d-25-hydroxylase-deficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643004","effects-of-high-dose-vitamin-d-on-hormones-neuromuscular-function-cognition-and-body-composition-in-athletes-100643004",false,"NCT07641075","Effects of High-Dose Vitamin D on Hormones, Neuromuscular Function, Cognition, and Body Composition in Athletes","The Effect of High-dose Vitamin D Supplementation on Selected Hormone Concentrations, Neuromuscular Transmission, Athletic Performance, Cognitive Functions, and Body Composition in Athletes.","Inclusion Criteria:\n\n* a minimum of 8 years of training experience,\n* absence of injuries in the 6 months leading up to the assessments,\n* consistent engagement in training sessions a minimum of 5 times per week over the last 6 months.\n\nExclusion Criteria:\n\n* vitamin D supplementation within one month prior to the study,\n* use of multivitamin supplements,\n* intestinal disorders.",true,"ALL","17 Years","60 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effects of high-dose vitamin D3 supplementation on selected physiological, neuromuscular, and cognitive parameters in athletes. At the baseline visit, participants will undergo a series of assessments at the Functional Research Laboratory at AWF Katowice, including a 10 mL venous blood sample collection, body composition analysis (via InBody and DEXA scans), neuromuscular function evaluation using tensiomyography (TMG), and computerized cognitive tests via the Vienna Test System.\n\nFollowing baseline testing, participants will be randomly assigned to either the vitamin D3 group or the placebo group. The active group will receive a daily dose of 4,000 IU of vitamin D3 (1 capsule with dinner), while the control group will receive an identical placebo. The intervention period will last for 4 or 8 weeks. Upon completion of the supplementation period, all baseline assessments will be repeated to evaluate the post-intervention changes.",[28,29],"Vitamin D 25-Hydroxylase Deficiency","Vitamin D Deficiency\u002FInsufficiency",[31,32,33,34,35,36,37],"vitamin D","athletes","coggnitive function","neuro-muscular function","hormones","speed","performance","RECRUITING","2026-06-08",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2025-07-01",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":50},"100621117","high-dose-vs-standard-ergocalciferol-for-vitamin-d-normalization-in-aggressive-non-hodgkin-lymphoma-100621117","NCT07366450","High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma","Safety and Efficacy of High-Intensity Loading Dose Versus Standard Weekly Dosing of Ergocalciferol (Vitamin D2) for Vitamin D Normalization in Patients With Newly Diagnosed Aggressive Non-Hodgkin Lymphoma: A Randomized, Open-Label, Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 20 years.\n* Newly diagnosed aggressive non-Hodgkin lymphoma, confirmed by histopathological examination according to the WHO Classification of Haematolymphoid Tumours, 5th edition, with an indication for standard first-line chemoimmunotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n* Serum 25-hydroxyvitamin D level \\\u003C 30 ng\u002FmL within 14 days prior to randomization.\n* Adequate organ function to receive full-dose standard chemotherapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Mild hypercalcemia (corrected Ca \\> 10.4 mg\u002FdL)\n* Hyperphosphatemia (PO4 \\> 4.5 mg\u002FdL)\n* History of urolithiasis associated with hypercalciuria or a diagnosis of primary hyperparathyroidism.\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Inability to take oral medication, active gastrointestinal bleeding, or malabsorption syndrome.\n* Pregnancy or breastfeeding.\n* Prior systemic therapy for lymphoma.\n* Ongoing tumor lysis syndrome requiring urgent treatment.\n* Prior use of vitamin D supplements (ergocalciferol or cholecalciferol).\n\nWithdrawal Criteria:\n\n* Development of mild hypercalcemia.\n* Development of mild hypophosphatemia.\n* Development of hypervitaminosis D.\n* Occurrence of severe adverse events (AEs) or side effects for which the investigator considers discontinuation of the study drug necessary for patient safety.\n* Investigator's judgment that continued participation may pose a safety risk, such as the occurrence of serious infection, febrile neutropenia, or organ failure.\n* Non-adherence to study medication, defined as cumulative vitamin D₂ intake of less than 80% of the expected cumulative dose at the time of serum vitamin D assessment.\n* Participant withdrawal of consent to continue participation in the study.","20 Years",{"count":60,"type":22},52,[25],"The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.\n\nThe main questions it aims to answer are:\n\n* Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?\n* Are there differences in safety and adverse events between the two dosing strategies?\n\nResearchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)\n* Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma\n* Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits\n* Be followed for treatment response, survival outcomes, and adverse events during and after therapy",[28,64],"Lymphoma Non-Hodgkin",[66,67,68,69],"Non-Hodgkin lymphoma","Vitamin D deficiency","Overall survival","Efficacy","NOT_YET_RECRUITING","2026-01-16",{"date":73,"type":42},"2026-01-26",{"date":75,"type":22},"2026-02-01",{"date":77,"type":22},"2029-07-31",{"name":79,"class":49},"Phramongkutklao College of Medicine and Hospital"]